8-K: Century Therapeutics Advances T1D and Autoimmune Therapies

Century Therapeutics reported Q2 2026 results, highlighting progress on CNTY-813 for Type 1 Diabetes with a pre-IND meeting with the FDA and strong preclinical data, alongside advancing CNTY-308 for autoimmune diseases, supported by a cash runway into Q1 2029.

Summary

• Century Therapeutics announced its financial results for the second quarter ended June 30, 2026.
• The company completed a pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy for Type 1 Diabetes (T1D), with an IND submission planned for Q4 2026.
• Preclinical data for CNTY-813 demonstrated durable glucose control and immune evasion, advancing its potential as a functional cure for T1D.
• CNTY-308, a CD19-targeted CAR-iT cell therapy, is on track to enter the clinic in 2026.
• The company reported cash, cash equivalents, and investments of $197.2 million as of June 30, 2026, providing an estimated cash runway into Q1 2029.
• Research and Development expenses decreased to $19.6 million in Q2 2026 from $26.9 million in Q2 2025, attributed to portfolio prioritization.
• General and Administrative expenses also decreased to $5.8 million from $7.8 million in the same period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with significant progress on key drug candidates and a strong cash position, indicating a well-managed and promising development pipeline.

Positives

• Successful pre-IND meeting with the FDA for CNTY-813, aligning on regulatory path and clinical trial design.
• Strong preclinical data for CNTY-813 showing durable glucose control and immune evasion, supporting its potential as a functional cure for T1D.
• Phase 1 manufacturing process for CNTY-813 established, demonstrating consistent product quality.
• CNTY-308 remains on track for clinical initiation in 2026.
• Significant cash position of $197.2 million as of June 30, 2026, extending cash runway into Q1 2029.
• Reduction in R&D expenses by $7.3 million year-over-year, indicating efficient resource allocation.
• Reduction in G&A expenses by $2.0 million year-over-year.

Negatives

• Net loss of $34.6 million for the quarter ended June 30, 2026, compared to a net loss of $32.5 million for the same period in 2025.
• R&D expenses, while reduced, remain substantial at $19.6 million for the quarter.

Risks

• Uncertainties inherent in the results of preliminary data, pre-clinical studies, and earlier-stage clinical trials, which may not be predictive of final results.
• Ability to obtain clearance of future IND or CTA submissions and commence and complete clinical trials on expected timelines.
• Reliance on the maintenance of certain key collaborative relationships for manufacturing and development.
• Timing, scope, and likelihood of regulatory filings and approvals.
• Impact of geopolitical issues, trade disputes, banking instability, and inflation on business operations and supply chain.
• Performance of third parties in clinical trials and manufacturing.
• Ability to successfully commercialize product candidates if approved.
• Ability to recruit and maintain key management personnel and enforce intellectual property protection.

Future Outlook

The company anticipates submitting an IND for CNTY-813 in Q4 2026 and expects CNTY-308 to enter the clinic in 2026. Initial clinical data for CNTY-813 is expected in the second half of 2027. The current cash position is projected to support operations into Q1 2029.

Management Comments

• "We are executing with speed against key development milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale," said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.
• "With CNTY-813, our preclinical data at ADA 2026 continue to support its potential as a functional T1D cure, and we have established our Phase 1 manufacturing process, demonstrating consistent product quality across independent batches."
• "Our recent pre-IND meeting with the FDA builds on that progress yielding alignment with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission on track for the fourth quarter of 2026."
• "In addition, CNTY-308 remains on track to enter the clinic in 2026."

Industry Context

StockSavvy.ai notes that Century Therapeutics is operating in the highly competitive and innovative biotechnology sector, focusing on cell therapies for autoimmune diseases and cancer. The company's progress with iPSC-derived therapies and immune-evasion technology places it at the forefront of developing potentially curative treatments, aligning with broader industry trends towards more targeted and potentially curative therapies.

Comparison to Industry Standards

• The company's cash runway into Q1 2029, supported by a $135M PIPE in early 2026, is a strong indicator of financial health compared to many early-stage biotech firms.
• The development of CNTY-813 as an iPSC-derived islet replacement therapy without chronic immunosuppression aims to overcome limitations seen with current islet transplantation methods and earlier stem-cell derived islet therapies like Vertex's VX-880, which still require immunosuppression.
• CNTY-308, a CAR-iT cell therapy for autoimmune diseases, leverages advancements in CAR-T technology, which has shown significant efficacy in oncology and is increasingly being explored for autoimmune conditions by companies like CARsgen Therapeutics and others.
• The company's in-house manufacturing capabilities for cell therapies are a strategic advantage, enabling greater control over scalability, quality, and cost, a model adopted by leading cell therapy developers.

Stakeholder Impact

• Shareholders: Positive outlook due to pipeline advancements and extended cash runway, potentially leading to future value creation.
• Patients with Type 1 Diabetes: Potential for a functional cure with CNTY-813, offering a significant improvement over current management strategies.
• Patients with Autoimmune Diseases: Advancement of CNTY-308 offers hope for new therapeutic options.
• Employees: Continued development and potential future commercialization may lead to growth and opportunities within the company.

Next Steps

• Submit IND for CNTY-813 in Q4 2026.
• Initiate clinical trial for CNTY-308 in 2026.
• Present CNTY-813 preclinical data at EASD 2026 and Breakthrough T1D CRC 2026.
• Expect initial clinical data for CNTY-813 in 2H 2027.

Key Dates

Recommendation

The company is making significant progress on its key pipeline assets, particularly CNTY-813 for Type 1 Diabetes, and has a strong cash position extending its runway. However, the company is still in the development phase with clinical data expected in 2H 2027, and faces inherent risks associated with drug development. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor upcoming milestones and clinical trial results.

Keywords

Type 1 Diabetes, iPSC, Cell Therapy, CNTY-813, CNTY-308, CAR-iT, Autoimmune Disease, FDA